Genetics, Biotechnology, Pharmaceuticals, Specialty Chemicals and allied fields are right at the leading edge of human knowledge development.

Developments such as these aren’t easy to achieve, but they have significant value – and that value needs to be incentivized, financed, protected, tested, deployed, commercialized and defended.

Industry experience

Withers’ lawyers regularly handle all types of work in these fields, serving a diverse range of clients – scientists, sponsors, manufacturers, distributors, investors.

Many have a technical or scientific background themselves, with PhDs on the team in all the key subject matters. Key leaders of the team even have in-house experience, including as chief patent counsel for a joint venture by two large pharmaceutical companies, enabling unique insight into the challenges and the opportunities – from the mundane to the sublime.

This combined experience means we can handle all your needs quickly and effectively. We understand the technology, the regulation, the competition, the capital constraints and returns within a commercial environment.

Protecting your interests

The wider landscape around pharmaceuticals and allied fields is uncertain. Businesses are adapting to shifts in politics and regulations, technology and markets.

That makes enabling your work even more important, and this is a huge priority for us. From prosecuting applications for new drugs, to drawing up agreements to protect know-how, to facilitating investments, spinoffs or mergers and acquisitions, to litigating infringements, the Withers team can help both recognize and realise the value of what you do.

For further help or information

Get in touch

Defining moments

What does it take to be successful and how do we navigate key moments in our lives? We explore stories of success with the FT.

Read more

07 May 2021 - Podcast

International impact investor, Mark Cheng, talks social entrepreneurship, business model innovation and purpose

Read More

19 April 2021 - Article

Withers expands international venture capital and life sciences team with launch in Boston

Read More


Leading firm in Asia Pacific 2015

Ranked nationally in the US for trusts and estates and tax law by Best Lawyers 2017

Meet the team

How we can help

Track record

Licensing of a new pharmaceutical drug product

Acted for an international pharmaceutical company in an evaluation project for the licensing of a new drug product as well as intellectual property litigation matters.

CEO of an international pharmaceutical company

We acted for the CEO of an international and award winning pharmaceutical company in relation to her acrimonious exit. As a co-founder of the business and a minority shareholder, we negotiated the terms of her multi-million pound settlement, working closing with one of the top four accountants on valuation issues.

US medical company

We were instructed to form a master LLC (limited liability company) to buy, build, own and occupy a state-of-the-art medical office building in the US. We also negotiated the permanent financing and construction, and arranged all the leases for our client.

Reorganization of a leading Californian pharmaceutical company

Advised, as lead investor counsel, in a reorganization, US$1 million bridge loan, and US$7 million strategic investment by a leading pharmaceutical company in a biotech/medical company based in California.

Biotech/healthcare merger and acquisition

Advised in the acquisition of and merger into a biotech/healthcare company based in North Carolina.

Acquisition of the U.S. subsidiary of a U.K. pharmaceutical company

Advised an Italian company in its acquisition of the U.S. subsidiary of a U.K. company in the pharmaceutical industry.

Sale of the South Beach Diet brand to MidOcean Partners

We represented the founders of the South Beach Diet in the sale of the South Beach Diet brand to MidOcean Partners, a leading private equity firm.

Acquisition of the minority shareholding in Australian pharmaceutical company

We acted for Lupin in relation to its acquisition of the minority shareholding in a pharmaceutical company in Australia.

Chinese medicine company

Acting for a sovereign wealth fund as a consortium member in the takeover of a major traditional Chinese medicine company.